XTL - SPDR S&P Telecom ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
69.6600
-1.0494 (-1.4841%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close70.7094
Open69.3500
Bid35.2100 x 100
Ask71.1400 x 200
Day's Range69.6600 - 70.4100
52 Week Range65.1000 - 74.6400
Volume9,661
Avg. Volume27,086
Net Assets104.98M
NAV69.99
PE Ratio (TTM)N/A
Yield2.03%
YTD Return2.61%
Beta (3y)0.92
Expense Ratio (net)0.35%
Inception Date2011-01-26
Trade prices are not sourced from all markets
  • Large Speculator Positions in S&P 500 for Week Ended January 26
    Market Realist22 days ago

    Large Speculator Positions in S&P 500 for Week Ended January 26

    This Week: Fed Meeting, Tech Biggies, and the Drowning Dollar

  • Telecommunications ETF Investing Guide
    Zacks2 months ago

    Telecommunications ETF Investing Guide

    Major telecommunications stocks did well in the third quarter, what lies ahead?

  • PR Newswire3 months ago

    XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has received notification from the NASDAQ Stock Market LLC ("NASDAQ") that the Company has regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 17, 2017, the Company received a notice from NASDAQ stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule") because the Company did not have a minimum stockholders' equity, as of June 30, 2017, of $2.5 million and the Company did not alternatively meet the market capitalization or income from continuing operations tests.

  • ETF Database4 months ago

    ETF Scorecard: November 3 Edition

    To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.

  • ETF Database4 months ago

    ETF Scorecard: October 20 Edition

    To help investors keep up with the markets, we present our ETF Scorecard. The Scorecard takes a step back and looks at how various asset classes across the globe are performing. The weekly performance is from last Friday’s open to this week’s Thursday close.

  • Market Realist6 months ago

    Will the S&P 500 Index Recover from Last Week’s Fall?

    The S&P 500 Index (SPY) closed last week at 2425.55, losing 0.65% as compared to its August 11 close.

  • Zacks6 months ago

    What Like Ahead for Telecom ETFs?

    We expect this industry to witness growth more or less in line with the broader market.

  • 5 Top Telecom ETFs
    Motley Fool7 months ago

    5 Top Telecom ETFs

    If you like telecom stocks, these funds have what you want.

  • Can Stock Market Keep Rising As Summer Doldrums Loom?
    Investor's Business Daily9 months ago

    Can Stock Market Keep Rising As Summer Doldrums Loom?

    Telecom, biotech and retail ETFs outperformed early Thursday as the market kicked off June with narrow gains.

  • PR Newswire10 months ago

    XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that Mr. Alex Rabinovich has been appointed as a member of the Company's board of directors. Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome

    RAANANA, Israel, April 5, 2017 /PRNewswire/ -- Additional data shows a statistically significant effect in the gene expression of two additional genes that have a role in the pathogenesis of Sj ö gren ...

  • PR Newswire11 months ago

    XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

    XTL Biopharmaceuticals Ltd. (XTLB) (XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has closed its private offering of securities for proceeds of $2.8 million. In connection with the offering, announced previously on March 7, 2017, the Company issued and sold 1,400,000 American Depository Shares (ADSs) at a purchase price of $2.00 per ADS. The Company has agreed to hold a shareholder meeting to increase its authorized ordinary shares to allow for the full exercise of the warrants (the "Authorized Capital Increase").

  • Zacks11 months ago

    5 Biggest Winners from the Fed Rate Hike

    The Fed dropped hints that it will not raise rates four times this year, a definite loss for the Wall Street and a win for the Main Street.

  • PR Newswirelast year

    XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

    As previously disclosed on November 14, 2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") had closed below US $1.00 per share for 30 consecutive business days. On February 28, 2017, XTL received notification from Nasdaq that the closing price of the Company's America Depository Share has been at $1.00 per share or greater for the last 10 consecutive business days from February 10 through 24, 2017.